341 related articles for article (PubMed ID: 26390218)
1. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
Furio L; Pampalakis G; Michael IP; Nagy A; Sotiropoulou G; Hovnanian A
PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218
[TBL] [Abstract][Full Text] [Related]
2. KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype.
Kasparek P; Ileninova Z; Zbodakova O; Kanchev I; Benada O; Chalupsky K; Brattsand M; Beck IM; Sedlacek R
PLoS Genet; 2017 Jan; 13(1):e1006566. PubMed ID: 28095415
[TBL] [Abstract][Full Text] [Related]
3. Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome.
Zingkou E; Pampalakis G; Sotiropoulou G
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165831. PubMed ID: 32442469
[TBL] [Abstract][Full Text] [Related]
4. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition.
Hovnanian A
Cell Tissue Res; 2013 Feb; 351(2):289-300. PubMed ID: 23344365
[TBL] [Abstract][Full Text] [Related]
5. A proinflammatory role of KLK6 protease in Netherton syndrome.
Zingkou E; Pampalakis G; Charla E; Nauroy P; Kiritsi D; Sotiropoulou G
J Dermatol Sci; 2019 Jul; 95(1):28-35. PubMed ID: 31255470
[TBL] [Abstract][Full Text] [Related]
6. Transgenic Kallikrein 14 Mice Display Major Hair Shaft Defects Associated with Desmoglein 3 and 4 Degradation, Abnormal Epidermal Differentiation, and IL-36 Signature.
Gouin O; Barbieux C; Leturcq F; Bonnet des Claustres M; Petrova E; Hovnanian A
J Invest Dermatol; 2020 Jun; 140(6):1184-1194. PubMed ID: 32169475
[TBL] [Abstract][Full Text] [Related]
7. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
[TBL] [Abstract][Full Text] [Related]
8. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.
Furio L; de Veer S; Jaillet M; Briot A; Robin A; Deraison C; Hovnanian A
J Exp Med; 2014 Mar; 211(3):499-513. PubMed ID: 24534191
[TBL] [Abstract][Full Text] [Related]
9. Cocktails of KLK5 Protease Inhibitors and Anti-TNFα Therapeutics: an Effective Treatment for Netherton Syndrome.
Zingkou E; Pampalakis G; Sotiropoulou G
J Clin Immunol; 2022 Apr; 42(3):597-605. PubMed ID: 35040012
[TBL] [Abstract][Full Text] [Related]
10. Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis.
Chavarria-Smith J; Chiu CPC; Jackman JK; Yin J; Zhang J; Hackney JA; Lin WY; Tyagi T; Sun Y; Tao J; Dunlap D; Morton WD; Ghodge SV; Maun HR; Li H; Hernandez-Barry H; Loyet KM; Chen E; Liu J; Tam C; Yaspan BL; Cai H; Balazs M; Arron JR; Li J; Wittwer AJ; Pappu R; Austin CD; Lee WP; Lazarus RA; Sudhamsu J; Koerber JT; Yi T
Sci Transl Med; 2022 Dec; 14(675):eabp9159. PubMed ID: 36516271
[TBL] [Abstract][Full Text] [Related]
11. Physiological and pathological roles of kallikrein-related peptidases in the epidermis.
Kishibe M
J Dermatol Sci; 2019 Aug; 95(2):50-55. PubMed ID: 31279501
[TBL] [Abstract][Full Text] [Related]
12. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model.
Briot A; Lacroix M; Robin A; Steinhoff M; Deraison C; Hovnanian A
J Invest Dermatol; 2010 Dec; 130(12):2736-42. PubMed ID: 20703245
[TBL] [Abstract][Full Text] [Related]
13. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis.
Fortugno P; Furio L; Teson M; Berretti M; El Hachem M; Zambruno G; Hovnanian A; D'Alessio M
Hum Mol Genet; 2012 Oct; 21(19):4187-200. PubMed ID: 22730493
[TBL] [Abstract][Full Text] [Related]
14. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum.
Ishida-Yamamoto A; Deraison C; Bonnart C; Bitoun E; Robinson R; O'Brien TJ; Wakamatsu K; Ohtsubo S; Takahashi H; Hashimoto Y; Dopping-Hepenstal PJ; McGrath JA; Iizuka H; Richard G; Hovnanian A
J Invest Dermatol; 2005 Feb; 124(2):360-6. PubMed ID: 15675955
[TBL] [Abstract][Full Text] [Related]
15. Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy.
Furio L; Hovnanian A
Biol Chem; 2014 Sep; 395(9):945-58. PubMed ID: 25153381
[TBL] [Abstract][Full Text] [Related]
16. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome.
Briot A; Deraison C; Lacroix M; Bonnart C; Robin A; Besson C; Dubus P; Hovnanian A
J Exp Med; 2009 May; 206(5):1135-47. PubMed ID: 19414552
[TBL] [Abstract][Full Text] [Related]
17. Genetic activation of Nrf2 reduces cutaneous symptoms in a murine model of Netherton syndrome.
Muzumdar S; Koch M; Hiebert H; Bapst A; Gravina A; Bloch W; Beer HD; Werner S; Schäfer M
Dis Model Mech; 2020 Jun; 13(5):. PubMed ID: 32457102
[TBL] [Abstract][Full Text] [Related]
18. A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.
Liddle J; Beneton V; Benson M; Bingham R; Bouillot A; Boullay AB; Brook E; Cryan J; Denis A; Edgar E; Ferrie A; Fouchet MH; Grillot D; Holmes DS; Howes A; Krysa G; Laroze A; Lennon M; McClure F; Moquette A; Nicodeme E; Santiago B; Santos L; Smith KJ; Thorpe JH; Thripp G; Trottet L; Walker AL; Ward SA; Wang Y; Wilson S; Pearce AC; Hovnanian A
J Invest Dermatol; 2021 Sep; 141(9):2272-2279. PubMed ID: 33744298
[TBL] [Abstract][Full Text] [Related]
19. Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.
White GV; Edgar EV; Holmes DS; Lewell XQ; Liddle J; Polyakova O; Smith KJ; Thorpe JH; Walker AL; Wang Y; Young RJ; Hovnanian A
Bioorg Med Chem Lett; 2019 Mar; 29(6):821-825. PubMed ID: 30691925
[TBL] [Abstract][Full Text] [Related]
20. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome.
Wiegmann H; Valentin F; Tarinski T; Liebau E; Loser K; Traupe H; Oji V
Br J Dermatol; 2019 Nov; 181(5):999-1008. PubMed ID: 30801672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]